195990 — ABPro Bio Co Income Statement
0.000.00%
- KR₩91bn
- KR₩92bn
- KR₩32bn
Annual income statement for ABPro Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 35,797 | 32,914 | 22,112 | 25,375 | 31,663 |
Cost of Revenue | |||||
Gross Profit | 5,602 | 3,928 | 1,619 | 1,269 | 616 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 46,440 | 37,875 | 22,612 | 35,270 | 68,617 |
Operating Profit | -10,643 | -4,961 | -500 | -9,894 | -36,954 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -41,207 | -9,675 | -8,145 | -25,658 | -16,056 |
Provision for Income Taxes | |||||
Net Income After Taxes | -44,755 | -9,740 | -8,145 | -25,742 | -15,629 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -58,972 | -10,030 | -8,145 | -25,742 | -15,629 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -58,972 | -10,030 | -8,145 | -25,742 | -15,629 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -171 | -38.7 | -61.1 | -89.8 | -20.8 |
Dividends per Share |